Open AccessLong-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Author(s) -
Filippo Ceccato,
Mattia Barbot,
Nora Albiger,
Marialuisa Zilio,
P Toni,
G. Luisetto,
Martina Zaninotto,
Nella Augusta Greggio,
Marco Boscaro,
Carla Scaroni,
Valentina Camozzi
Publication year - 2016
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-16-0104
Subject(s) - congenital adrenal hyperplasia , medicine , endocrinology , glucocorticoid , 21 hydroxylase , bone mineral , hyperplasia , osteoporosis
Patients with 21-hydroxylase deficiency (21OHD) assume a lifelong glucocorticoid (GC) therapy. Excessive GC treatment increases the risk of osteoporosis and bone fractures, even though the role of substitutive therapy is not fully established: we analyzed the effect of GC dose on bone metabolism and bone mineral density (BMD) over time in patients with 21OHD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom